Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551797 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.
A Phase 1 study of Pain, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01551797: Completed Phase 1 study of Pain, sponsored by GlaxoSmithKline.
NCT01551797 is a Phase 1 study of Pain that has completed, run by GlaxoSmithKline. The registered enrollment target is 14 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01551797, a Phase 1 study of Pain, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This proof of principle study will evaluate an experimental formulation of paracetamol that is being developed for eventual long lasting use. This study is also used for drug safety evaluation.
Primary Outcome
Time period in hours over which plasma paracetamol concentration is elevated at or above 4 micrograms (μg)/milliliter (mL).
Conditions Studied
Interventions
- DRUG Paracetamol 500 mg
- DRUG Paracetamol 1000 mg
- DRUG Paracetamol 750 mg
Study Locations (1)
Washington
- Charles River Clinical Services Northwest, Inc. - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2010-05 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
What the finished NCT01551797 record still lists
NCT01551797 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 3 interventions - of which Paracetamol 500 mg is the first listed.
NCT01551797 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT01551797 about?
NCT01551797 is a clinical study titled "A Pharmacokinetic Study to Compare Sustained Release and Standard Paracetamol Formulations.". This proof of principle study will evaluate an experimental formulation of paracetamol that is being developed for eventual long lasting use. This study is also used for drug safety evaluation.
What is the current status of trial NCT01551797?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2010-05. Estimated completion is 2010-10.
What conditions does trial NCT01551797 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT01551797?
The interventions under investigation include: Paracetamol 500 mg (DRUG), Paracetamol 1000 mg (DRUG), Paracetamol 750 mg (DRUG).
Who is sponsoring clinical trial NCT01551797?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01551797 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01551797's enrollment target sits among peer trials
14 355th of 374 higher than 19 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
RECRUITING · Phase 1
-
Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
RECRUITING · Phase 1
-
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery
RECRUITING · Phase 1
-
High Potency Cannabis: Acute and Protracted Effects
RECRUITING · Phase 1
-
Phase 1 Study of SBS-147 in Healthy Adults
RECRUITING · Phase 1
-
Patient Controlled Administration of Liquid Acetaminophen
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia